Results 211 to 220 of about 8,914,547 (304)

International multisite implementation of distributed cell-free protein biomanufacturing to advance health and research equity. [PDF]

Sci Adv
da Silva SJR, Matthews Q, Cazaux S, Vigar JRJ, Santos BNR, Carvalho DCM, Cranmer LA, Duplat D, Singh S, Simchi M, Benítez-Bolivar P, de Lima Cavalcanti TYV, Wu K, Mendes RPG, Kale T, Divarzak ALL, Bozovicar K, Doucet J, Arce A, Léon C, Ferrando V, Nguyen J, Ho A, de Lima SC, Bayat P, Guo Y, Cicek S, Tinafar A, Krokovsky L, Machado LC, Rayhan A, Iwe IA, Klenov A, de Araujo TPG, Nascimento JPM, Magalhães JJF, Guevara-Suarez M, Garcia Canete P, Ayi K, Charania M, Stehelin TE, Chatfield-Reed K, Paiva MHS, Crandall I, Mazzulli T, da Luz Wallau G, Silva-Júnior A, Bernal A, Athale CA, Green AA, Weaver SC, González C, Federici F, Pena L, Pardee K.   +54 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Cell-Free DNA Uncovered Tumor Heterogeneity and Informed Targeted Therapy in a Pediatric Rhabdomyosarcoma. [PDF]

JCO Precis Oncol
Faucher J, Richer C, Langlois S, Rouette A, Bianco S, Sontag T, Lepage MÈ, Da Silva E, Cellot S, Tran TH, Parbhoo K, Cottrell CE, Sinnett D, Michon B, Lavallée VP, Santiago R.   +15 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Donor-derived Cell-free DNA for Detection of Rejection After Pancreas Transplantation. [PDF]

Transplant Direct
Matar AJ, Riad S, Sarumi H, Megaly MG, Wright M, Finger E, Humphreville V, Ramanathan K, Fisher J, Rao JS, Demko Z, Prewett A, Tabriziani H, Kandaswamy R.   +13 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Mesenchymal Stem/Stromal Cell-Free Therapies: Challenges and Opportunities. [PDF]

Mol Biotechnol
Wong RS, Tan EW, Ng NC, Goh BH.
europepmc   +1 more source